To gain insights into the potential molecular mechanisms underlying the prognostic observation, we performed a series of GEP analyses comparing p63+ and p63− patients in the overall DLBCL group and various subsets stratified by GCB/ABC subtype, TP53 mutation and p53 overexpression status (Fig 6A-H, Supplemental Fig S3A-D). The gene discussed is TP63; the disease is diffuse large B-cell lymphoma.